Does Methylene Blue Protect the Kidney Tissues from Damage Induced by Ciclosporin A Treatment?

Abstract

Ciclosporin A (CsA) is the first-choice immunosuppressant universally used in allotransplantation and autoimmune diseases. However, it has been demonstrated that this drug produces negative side effects in several organs and in particular in the lymphoid organs and in the kidney. It has been suggested that the CsA causes deleterious effects because it increases the oxygen free radical production. Here we wanted to test whether antioxidants protect the kidney parenchyma from the toxicity induced by CsA. We used methylene blue (MB), because it inhibits the formation of oxygen free radicals. The study was carried out in four groups of Wistar rats. Group I animals were intraperitoneally injected with MB (1 mg/kg/day) for 21 days; group II animals were subcutaneously injected with CsA (15 mg/kg/day) for 21 days; group III animals were treated with CsA combined with MB at the same doses and for the same periods as groups I and II, and group IV animals were injected subcutaneously with olive oil for 21 days as controls. The kidneys and the thymuses were subsequently removed and examined by conventional morphological staining (hematoxylin-eosin and Masson’s trichrome) and enzymatic (NADPH-diaphorase, cytochrome, c oxidase, and superoxide anion production) and immunoenzymatic (inducible nitric oxide synthase – iNOS, endothelial nitric oxide synthase – eNOS) techniques. The thymuses were used to check the persistence of CsA-immunsuppressive effects during MB administration. Group I, III, and IV animals showed a normal kidney architecture and low levels of NADPH-diaphorase and of superoxide anion in all structures studied (proximal and distal tubules, glomeruli and the Henle loops). The cytochrome c oxidase showed a strong activity in proximal tubules, a moderate activity in distal tubules, and a weak activity in glomeruli and in the Henle loops. The expression of iNOS was weak in the proximal tubular epithelial cells and negative in the glomeruli, while eNOS was found to be moderately positive in the glomeruli and in the interstitial arteries, but not in the tubules and in the Henle loops. Degenerative changes with tubulointerstitial injury in the cortex of CsA-treated kidneys (group II) and increases of NADPH-diaphorase levels, iNOS activity, and superoxide staining were found in all structures. The expression of eNOS did not change in group I, III and IV animals. MB combined with CsA prevented the degenerative changes caused by CsA, preserving the structural, enzymatic, and immunoenzymatic integrity of the renal parenchyma. The mechanism by which MB exerts its protective action is not yet clear, but it seems to be due to its ability to inhibit xanthine oxidase and to quench nitric oxide production. Moreover, these data have been also supported by the following: (1) the superoxide anion levels were very high after CsA treatment and reduced after CsA-MB treatment, and (2) the iNOS levels increased in CsA-treated rats and showed normal levels after CsA-MB treatment. Moreover we demonstrated that MB administration did no co...

The comparison of methylene blue and vitamin E in prevention of abdominal postoperative adhesion formation in rat uterine horn models: Biochemical and histopathologic evaluation

“…The results obtained in the present study are similar to those reported by some researchers [28][29][30] but differ from those reported by Rezzani et al 31 and Aksu et al 32 . The differences may be due to the difference in organ systems used, the dose and mode of application of the MB used in these studies.…”

“…On the contrary, systemic administration of MB has been shown to reduce oxidative stress in kidney of ciclosporine treated rats 31 . Aksu et al 32 reported that administration of MB (2 mg/kg i.p.)…”

Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection

“…As a century-old drug, MB has been in medical use for many years in various pathological conditions (41,42). The therapeutic potential of MB has been demonstrated clinically against many diseases, including endotoxin-induced lung injury, bacterial lipopolysaccharide-induced fever (43)(44)(45), cyclosporin-induced kidney injury (46), doxorubicin-induced heart injury (47), and pancreas injury induced by streptozotocin (48). Recently, MB was reported to attenuate Tau aggregation, and it is currently in phase II clinical trials for treatment of Alzheimer disease.…”

Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase

“…MB has been shown to protect against cyclosporine injury to the kidney [142] and streptozotocin injury to the pancreas [143]. MB also protects from ischemic-reperfusion injury [144], radiation [145], and enhances β-oxidation of long chain fatty acids [146].…”